Werewolf Therapeutics, Inc. (HOWL)
Nasdaq: HOWL · Pharmaceutical Preparations · Watertown, MA · filing with the SEC since 2019
Who owns Werewolf Therapeutics, Inc.
As filed with the SECHolders of 5% or more
1
Moll Peter holds 5.2% of Common stock 0,0001$ per share, as its SCHEDULE 13G filed Sep 21, 2026 says.
Directors and officers
6
report now, of 23 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Moll Peter
SCHEDULE 13G · filed Sep 21, 2026 · Common stock 0,0001$ per share
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Jul 2, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6% in Jun 26, 2026
Ansbert Gadicke
SCHEDULE 13D/A · filed May 12, 2026 · Common Stock · reported falling below 5%, from 5.4% in May 5, 2026
Longwood Fund III GP, LLC
SCHEDULE 13G/A · filed Feb 11, 2026 · Common Stock · reported falling below 5%
PFM Health Sciences, LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common stock, par value $0.0001 per share (the "Shares") · reported falling below 5%, from 6.5% in Feb 14, 2025
What HOWL reports owning in othersstakes of 5% or more, and other ties
Werewolf Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
107sales
0purchases
87sales on a scheduled plan
3people selling
$4.2Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 43 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Evnin Luke | director | 87 | $3.3M | 87 | 0 | $0 |
| Mpm Bioventures 2014 LLC | 10% owner | 12 | $1.1M | 12 | 0 | $0 |
| Ubs Oncology Impact Fund L.P. | 10% owner | 10 | $800,000 | 10 | 0 | $0 |
| Ra Capital Management, L.P. | director | 14 | $700,000 | 0 | 0 | $0 |
| Mpm Asset Management Investors Bv2014 LLC | 10% owner | 6 | $500,000 | 6 | 0 | $0 |
| Mpm Oncology Impact Management LP | 10% owner | 6 | $500,000 | 6 | 0 | $0 |
| Mpm Oncology Innovations Fund Gp LLC | 10% owner | 9 | $500,000 | 9 | 0 | $0 |
| Mpm Oncology Innovations Fund LP | 10% owner | 3 | $400,000 | 3 | 0 | $0 |
| Kolchinsky Peter | director | 6 | $300,000 | 0 | 0 | $0 |
| Mpm Bioventures 2014 (B), L.P. | 10% owner | 3 | $200,000 | 3 | 0 | $0 |
| Mpm Bioventures 2014 Gp LLC | 10% owner | 3 | $200,000 | 3 | 0 | $0 |
| Mpm Bioventures 2014, L.P. | 10% owner | 4 | $200,000 | 4 | 0 | $0 |